Chromosome Alterations Contribute to Drug Resistance in ER+ Breast Cancer

Professor Susan Clark and colleagues at the Garvan Institute of Medical Research showed that the 3D structure of DNA is 'rewired' in hormone resistant ER+ breast cancers, altering normal gene activation and repression in the cells.

Chromosome Alterations Contribute to Drug Resistance in ER+ Breast Cancer

Professor Susan Clark and colleagues at the Garvan Institute of Medical Research showed that the 3D structure of DNA is 'rewired' in hormone resistant ER+ breast cancers, altering normal gene activation and repression in the cells.
Business people on video conference

Genetic Counseling 2.0

As genetic testing ramps up in the clinic and via consumer-oriented providers, companies leverage technology to scale genetic counseling services.

Illumina Debuts Two New Sequencers, Inks Dx Deal with Roche

The NextSeq 2000 and NextSeq 1000 are both designed to meet growing demand for clinical genomic data at reduced cost, while the collaboration with Roche is focused on advancing clinical diagnostics leveraging Illumina’s pan-cancer assay TruSight Oncology 500.
Illustration of a cancer cell

Researchers Discover New Gene Interaction Responsible for Cancer Metastasis

Investigators discovered that MYC and TWIST1, two transcription factors, together elicit a cytokinome whose signaling enabled crosstalk between cancer cells and host macrophages—driving tumor progression.
Dendritic cell and T-lymphocytes, illustration

Johns Hopkins Researchers Refine TMB Calculations of Immunotherapy Response

The team developed a computational approach to estimate corrected TMB values for each tumor by simulating 20,000 tumors with various levels of TMB and sequencing coverage using information from the Cancer Genome Atlas to generate a correction factor for each simulated tumor based on its purity.

Chromosome Alterations Contribute to Drug Resistance in ER+ Breast Cancer

Professor Susan Clark and colleagues at the Garvan Institute of Medical Research showed that the 3D structure of DNA is 'rewired' in hormone resistant ER+ breast cancers, altering normal gene activation and repression in the cells.
Fabric Genomics is partnering with data management company ITTM to provide secure genomic data hosting capabilities for European customers. (Source: iStock/© evryka23)

Large Scale Genomic Study Uncovers New Disease Targets

Children’s Hospital of Philadelphia researchers compared the sequence data of more than 100,000 people of European ancestry and found copy number variant (CNV) associations in four major disease categories: autoimmune, cardio-metabolic, oncologic, and neurological/psychiatric diseases.
Nurse helping patient in hospital bed take a drink

Probiotic Drink Spiked with Genetic Elements Helps Thwart Antimicrobial Resistance

The drink targets small DNA elements called plasmids that carry antibiotic resistance genes. By preventing these plasmids from replicating, the antibiotic resistance genes are displaced, effectively re-sensitizing the bacteria to antibiotics.

Liquid Biopsy Test to Detect TRK Biomarkers in the Blood of Patients Diagnosed with Cancer

Biocept's Target Selector test enables physicians to identify the potential presence of NTRK fusions used to inform on treatment options.
ersonal Genome Diagnostics (PGDx) said today that its 500+ gene pan-cancer tumor profiling tissue assay is being used by Merck & Co. in a Phase II clinical trial designed to assess patient response to a dual biomarker-directed precision oncology combination therapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC).

Amgen Taps Guardant, Qiagen for AMG 510 NSCLC Companion Dx Partnerships

The deals with each partner will initially focus on the KRAS G12C mutation as found in non-small cell lung cancer (NSCLC), which accounts for approximately 13% of all NSCLC cases.
Fluidigm and Genomenon plan to create a joint panel design offering intended to help researchers accelerate the design of disease-specific next-generation sequencing

Element Biosciences Raises $80M to Accelerate Development of a New DNA Sequencing Platform

Led by ex-Illumina executives, Element’s founders believe its sequencing technology can reduce costs and inject more competition into a market dominated by their former employer.
DNA research concept DNA barcodes for biomedical research  mitochondrial DNA  Prostate cancer DNA test

8 Companion Diagnostic Developers Making a Mark

If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark (since acquired by Agilent Technologies) received authorization to market HercepTest. The immunohistochemistry (IHC) assay was designed to detect human epidermal growth factor receptor 2 (HER2)...

LeukoVantage: A Quest/QIAGEN Partnership Providing Clinical Insights Into Myeloid Malignancies

In this webinar, we will describe Quest’s LeukoVantage assay, an NGS test designed specifically for detecting clinically relevant variants in myeloid malignancies, and its partnership with N-of-One, a QIAGEN company, for expert interpretation.

Single-Cell Functional Proteomics Accelerates Immunotherapy Development Opportunities from Pre-Clinical to Clinical Stages

IsoPlexis’ next generation systems provide actionable potency, safety, and patient difference metrics by detecting highly potent single cell functional subsets for the first time.

The Next Era in Pathway Proteomics: Turnkey Targeted Quantitation Workflows

REGISTER NOW Broadcast Date: October 1, 2019 Time: 8:00 am PT, 11:00 am ET, 17:00 CET Accurate monitoring of cell signaling pathway proteins, particularly tyrosine phosphorylation (pTyr)...
Scroll Up